Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Medtronic plc (MDT)
Price$94.17Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B | $30.12B | $28.91B | $30.56B | $29.95B | $29.71B | $28.83B | $20.26B | $17.00B | $16.59B |
| Gross profit | $23.64B | $21.91B | $21.15B | $20.51B | $21.54B | $19.63B | $19.49B | $21.40B | $20.90B | $20.42B | $19.69B | $13.95B | $12.67B | $12.46B |
| Gross margin | 65.02% | 65.32% | 65.34% | 65.67% | 67.98% | 65.19% | 67.41% | 70.04% | 69.77% | 68.73% | 68.29% | 68.86% | 74.52% | 75.13% |
| Research & development | $2.87B | $2.73B | $2.73B | $2.70B | $2.75B | $2.49B | $2.33B | $2.33B | $2.26B | $2.19B | $2.22B | $1.64B | $1.48B | $1.56B |
| Operating expenses | $17.18B | $15.95B | $16.00B | $15.02B | $15.79B | $15.15B | $14.70B | $15.13B | $14.26B | $15.04B | $14.33B | $10.19B | $8.86B | $8.06B |
| Operating income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B | $4.48B | $4.79B | $6.27B | $6.64B | $5.38B | $5.36B | $3.77B | $3.81B | $4.40B |
| Operating margin | 17.78% | 17.76% | 15.89% | 17.56% | 18.15% | 14.89% | 16.57% | 20.51% | 22.17% | 18.12% | 18.59% | 18.59% | 22.42% | 26.53% |
| EBITDA | $9.43B | $8.82B | $7.79B | $8.18B | $8.46B | $7.19B | $7.45B | $8.93B | $9.28B | $8.30B | $8.18B | $5.07B | $4.66B | $5.22B |
| EBITDA margin | 25.92% | 26.29% | 24.07% | 26.20% | 26.70% | 23.86% | 25.78% | 29.21% | 31.00% | 27.94% | 28.37% | 25.03% | 27.42% | 31.47% |
| Net income | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B | $3.61B | $4.79B | $4.63B | $3.10B | $4.03B | $3.54B | $2.67B | $3.06B | $3.47B |
| Net profit margin | 13.20% | 13.90% | 11.36% | 12.03% | 15.90% | 11.97% | 16.56% | 15.16% | 10.36% | 13.56% | 12.27% | 13.20% | 18.02% | 20.90% |
| Basic EPSper basic share | $3.75 | $3.63 | $2.77 | $2.83 | $3.75 | $2.68 | $3.57 | $3.44 | $2.29 | $2.92 | $2.51 | $2.44 | $3.06 | $3.40 |
| Diluted EPSper diluted share | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 | $2.48 | $2.41 | $3.02 | $3.37 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 8, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 228 | $80.45 | $18.3K | 37.2K |
| Jun 8, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 4.0K | $80.44 | $318.6K | 37.5K |
| Feb 19, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 385 | $97.82 | $37.7K | 32.8K |
| Feb 19, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 668 | $97.83 | $65.4K | 33.2K |
| Feb 19, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 19.3K | $97.77 | $1.88M | 33.8K |
Community posts
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...